Professor, Internal Medicine, University of Texas Southwestern Medical Center, Southwestern Medical School
Internal Medicine
Dr. Scott M. Grundy, MD
|
|
Give Review
Scott M. Grundy is an expert in the field of Internal Medicine. He graduated from Baylor College of Medicine. He received 1 awards: "Elected Member". Scott Grundy is also published. He has 101 publications published. The lastest publication: "Cholesterol Efflux Capacity as a Therapeutic Target: Rationale and Clinical Implications.'
Publications
- Cholesterol Efflux Capacity as a Therapeutic Target: Rationale and Clinical Implications.
- Adipose tissue and metabolic syndrome: too much, too little or neither.
- Next Steps in Primary Prevention of Coronary Heart Disease: Rationale for and Design of the ECAD Trial.
- Is There a Gradient of Mortality Risk Among Men with Low Cardiorespiratory Fitness?
- Statins for All?
- Triglyceride-to-High-Density-Lipoprotein-Cholesterol Ratio Is an Index of Heart Disease Mortality and of Incidence of Type 2 Diabetes Mellitus in Men.
- Ethnic and Gender Susceptibility to Metabolic Risk.
- Relation of Regional Fat Distribution to Left Ventricular Structure and Function.
- Plasma Non-Cholesterol Sterols as Indicators of Cholesterol Absorption.
- Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults.
- Fasting Glucose, Obesity, and Metabolic Syndrome as Predictors of Type 2 Diabetes: The Cooper Center Longitudinal Study.
- Influence of upper and lower body adipose tissue on insulin sensitivity in South asian men.
- Cardiorespiratory Fitness, LDL Cholesterol, and Coronary Heart Disease Mortality in Men.
- Fat Distribution and Insulin Resistance in Young Adult Nonobese Asian Indian Women.
- Adiponectin as an Independent Predictor of the Presence and Degree of Hepatic Steatosis in the Dallas Heart Study.
- Cardiorespiratory Fitness and Metabolic Risk.
- AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update A Guideline From the Americ...
- AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the Ameri...
- Interview with Dr. Scott Grundy during AHA EPI/NPAM Meeting in March 2011.
- The Effect of Angiotensin Receptor Blockade on Insulin Sensitivity and Endothelial Function in Abdominally Obese Hypertensive Patients with Impaired Fasting Glucose.
- Effect of Colesevelam Hydrochloride on Glycemia and Insulin Sensitivity in Men With the Metabolic Syndrome.
- Comparisons of apolipoprotein B levels estimated by immunoassay, nuclear magnetic resonance, vertical auto profile, and non-high-density lipoprotein cholesterol in sub...
- ENPP1/PC-1 K121Q and other predictors of posttransplant diabetes.
- Clinical characteristics, vascular function, and inflammation in women with angina in the absence of coronary atherosclerosis: the Dallas Heart Study.
- Body size misperception: a novel determinant in the obesity epidemic.
- Prevalence of the metabolic syndrome as influenced by the measure of obesity employed.
- Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin.
- Sex differences in the relationship between C-reactive protein and body fat.
- Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patie...
- Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study).
- Effect of a high-fiber diet compared with a moderate-fiber diet on calcium and other mineral balances in subjects with type 2 diabetes.
- Evaluation of coronary artery calcium screening strategies focused on risk categories: the Dallas Heart Study.
- Genome-wide linkage and association analyses to identify genes influencing adiponectin levels: the GEMS Study.
- Ethnic differences in hepatic steatosis: an insulin resistance paradox?
- AJC editor's consensus: psoriasis and coronary artery disease.
- Variable contributions of fat content and distribution to metabolic syndrome risk factors.
- Comparison of effectiveness of atorvastatin 10 mg versus 80 mg in reducing major cardiovascular events and repeat revascularization in patients with previous percutane...
- Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline.
- Application of the screening for Heart Attack Prevention and Education Task Force recommendations to an urban population: observations from the Dallas Heart Study.
- Metabolic syndrome pandemic.
- Promise of low-density lipoprotein-lowering therapy for primary and secondary prevention.
- Thyroid mimetic as an option for lowering low-density lipoprotein.
- Lipid, glycemic, and insulin responses to meals rich in saturated, cis-monounsaturated, and polyunsaturated (n-3 and n-6) fatty acids in subjects with type 2 diabetes.
- Ten-year cardiovascular disease risk of metabolic syndrome without central obesity in middle-aged chinese.
- Cardiovascular and metabolic risk factors: how can we improve outcomes in the high-risk patient?
- Metabolic correlates of nonalcoholic fatty liver in women and men.
- The association of differing measures of overweight and obesity with prevalent atherosclerosis: the Dallas Heart Study.
- The editor's roundtable: high-density lipoprotein cholesterol.
- Serum insulin and inflammatory markers in overweight individuals with and without dyslipidemia.
- Ethnic differences in the frequency of ENPP1/PC1 121Q genetic variant in the Dallas Heart Study cohort.
- Ten-year risk of cardiovascular incidence related to diabetes, prediabetes, and the metabolic syndrome.
- Harmonizing the definition of the metabolic syndrome: comparison of the criteria of the Adult Treatment Panel III and the International Diabetes Federation in United S...
- Metabolic syndrome: a multiplex cardiovascular risk factor.
- Gamma-glutamyl transferase: another biomarker for metabolic syndrome and cardiovascular risk.
- Insulin resistance and body fat distribution in South Asian men compared to Caucasian men.
- Metabolic syndrome phenotype in very obese women.
- Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease.
- Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study.
- Influence of body fat content and distribution on variation in metabolic risk.
- Metabolic syndrome and hyperglycemia: congruence and divergence.
- Does the metabolic syndrome exist?
- Ethnic-specific criteria for the metabolic syndrome: evidence from China.
- Does a diagnosis of metabolic syndrome have value in clinical practice?
- Role of genetic polymorphism peroxisome proliferator-activated receptor-gamma2 Pro12Ala on ethnic susceptibility to diabetes in South-Asian and Caucasian subjects: Evi...
- Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds.
- Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels.
- Diabetes and coronary risk equivalency: what does it mean?
- Relationship between C-reactive protein and subclinical atherosclerosis: the Dallas Heart Study.
- Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement.
- Atherogenic dyslipidemia associated with metabolic syndrome and insulin resistance.
- Metabolic syndrome scientific statement by the American Heart Association and the National Heart, Lung, and Blood Institute.
- Trends in serum lipids and lipoproteins of adults, 1960-2002.
- Multiple QTLs influencing triglyceride and HDL and total cholesterol levels identified in families with atherogenic dyslipidemia.
- Race and gender differences in C-reactive protein levels.
- Point: the metabolic syndrome still lives.
- Joint distribution of non-HDL and LDL cholesterol and coronary heart disease risk prediction among individuals with and without diabetes.
- The changing face of cardiovascular risk.
- Stanol esters as a component of maximal dietary therapy in the National Cholesterol Education Program Adult Treatment Panel III report.
- Responsiveness of plasma lipids and lipoproteins to plant stanol esters.
- History and development of plant sterol and stanol esters for cholesterol-lowering purposes.
- The issue of statin safety: where do we stand?
- Influence of extended-release nicotinic acid on nonesterified fatty acid flux in the metabolic syndrome with atherogenic dyslipidemia.
- ENPP1/PC-1 K121Q polymorphism and genetic susceptibility to type 2 diabetes.
- Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial).
- Relation between atherogenic dyslipidemia and the Adult Treatment Program-III definition of metabolic syndrome (Genetic Epidemiology of Metabolic Syndrome Project).
- A constellation of complications: the metabolic syndrome.
- Atherosclerosis imaging and the future of lipid management.
- No association between plasma levels of plant sterols and atherosclerosis in mice and men.
- Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity.
- Richard Havel, Howard Eder, and the evolution of lipoprotein analysis.
- Metabolic syndrome: part II.
- Cholesterol gallstones: a fellow traveler with metabolic syndrome?
- Principles for national and regional guidelines on cardiovascular disease prevention: a scientific statement from the World Heart and Stroke Forum.
- Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?
- Metabolic syndrome: part I.
- Adipose tissue metabolites and insulin resistance in nondiabetic Asian Indian men.
- Obesity, metabolic syndrome, and cardiovascular disease.
- What is the contribution of obesity to the metabolic syndrome?
- Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association.
- Inflammation, hypertension, and the metabolic syndrome.
Schools
Baylor University
Doctors Specialties
- Other
- Internal Medicine
Accepted Insurances
Awards
- Elected Member
Education
-
Baylor College of Medicine
Hospital
-
University of Texas Southwestern Medical Center -
Veterans Affairs North Texas Health Care System
Helpful Reviews
Similar Doctors
|
|
Dr. Nancy Chen, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Charles R. Roe, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Corinthia McLeroy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John G. Casey, MD |
|
|
Dr. Jennifer L. Duewall, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Swati Namburi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tonia T. Yee, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Nabeel Farah, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gerald A. Schneider, MD |
|
|
Dr. Michelle M. Ho, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Blake R. Barker, MD
This Doctor is OpenDoctor Recommended.
|